SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

SI-BONE, Inc. (NASDAQ: SIBN), a leader in surgical solutions for sacropelvic disorders, announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. Management will hold a fireside chat on September 14, 2022, at 8:00 a.m. Eastern Time. A live webcast and an archived recording will be available on the company’s website for 90 days post-event. SI-BONE has pioneered the iFuse Implant System since 2009, enabling over 70,000 minimally invasive SI joint fusion procedures, supported by extensive clinical evidence and universal insurance coverage.

SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management will be hosting a fireside chat presentation on Wednesday, September 14th, 2022, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

A live webcast of each event, as well as an archived recording will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, more than 2,800 surgeons have performed a combined total of more than 70,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish near universal coverage of the SI joint fusion procedure. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research, and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE participate in the Morgan Stanley 20th Annual Global Healthcare Conference?

SI-BONE will participate in the conference on September 14, 2022, at 8:00 a.m. Eastern Time.

Where can I watch the SI-BONE presentation from the Morgan Stanley conference?

The presentation will be available via a live webcast on SI-BONE's website, and it will be archived for 90 days.

What is the significance of the iFuse Implant System by SI-BONE?

The iFuse Implant System has facilitated over 70,000 minimally invasive surgeries for SI joint fusion, establishing SI-BONE as a market leader.

How long has SI-BONE been in the medical device industry?

SI-BONE has been operating since 2009, focusing on surgical treatments for musculoskeletal disorders.